Europe approves Merck’s plant to make J&J COVID-19 vaccine – Reuters

A vial of the Johnson & Johnson’s coronavirus disease (COVID-19) vaccine is seen at Northwell Health’s South Shore University Hospital in Bay Shore, New York, U.S., March 3, 2021. REUTERS/Shannon Stapleton/File Photo

Oct 7 (Reuters) – The European Medicines Agency (EMA) said on Thursday it had approved U.S. drugmaker Merck & Co Inc’s (MRK.N) manufacturing site in West Point, Pennsylvania to make Johnson & Johnson’s (JNJ.N) COVID-19 vaccine.

Earlier this year, Merck agreed to make its rival’s shot, after scrapping two of its own experimental COVID-19 vaccines. read more

The U.S. government at that time invoked the Defense Production Act to help equip two Merck plants to make the J&J vaccine.

The EMA said Merck’s site, to become operational immediately, was expected to support the continued supply of J&J’s COVID-19 vaccine in the European Union.

Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli

Our Standards: The Thomson Reuters Trust Principles.